Communiqués Basilea Pharmaceutica AG

Actions

BSLN

CH0011432447

Marché Fermé - Swiss Exchange Autres places de cotation 17:30:19 12/06/2024			Varia. 5j.	Varia. 1 janv.
42 ^CHF	+1,20 %		+0,24 %	+18,98 %

16/05	Basilea perçoit un versement d'étape de Pfizer de plus d'un million de dollars	AW
16/05	Basilea Pharmaceutica reçoit un paiement d'étape de Pfizer pour les ventes de Cresemba	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	16/05	GL
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024	03/05	GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	24/04	GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	24/04	AQ
Actym Therapeutics Appoints Thomas Smart as CEO	24/04	PR
Basilea Pharmaceutica : Updated April 9, 2024	09/04	PU
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics	09/04	GL
Basilea Pharmaceutica : Updated April 4, 2024	04/04	PU
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications	04/04	GL
Basilea Pharmaceutica : Updated April 3, 2024	03/04	PU
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	11/03	GL
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	11/03	AQ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	GL
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	DJ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	AQ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea	19/01	GL
Cresemba(R) sales in Latin America trigger first sales milestone payment to Basilea	19/01	DJ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea	19/01	AQ
Basilea announces acquisition of preclinical antibiotics program from Spexis	15/01	GL
Basilea announces acquisition of preclinical antibiotics program from Spexis	15/01	DJ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Basilea Pharmaceutica AG

Actions

BSLN

CH0011432447

Communiqués

Filtres